Family people initiative

Retina Health May Indicate Alzheimer’s Risk, Study Says

Reading now: 138

nationwide A4 study on anti-amyloid treatment for Alzheimer’s. The landmark study launched in 2014 assessed whether the investigational drug, solanezumab, could slow memory loss caused by the amyloid protein.

ADVERTISEMENTThe study invited older individuals (ages 65-85) who have normal cognition and memory but who may be at risk for developing Alzheimer’s to participate.

Researchers then used an imaging test called a PET scan with over 4,400 participants to measure amyloid buildup in the brain.

The website is an aggregator of articles from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the article if you find it unreliable.

Related articles